LAST 0.025
CHANGE 0.000
LAST: 0.025
CHANGE: 0.000
FSE: 18H
Download as PDF  

PreveCeutical Announces Further Successful Results from The Sol-Gel Program Final Report

Vancouver, British Columbia:  PreveCeutical Medical Inc. (“PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), is pleased to announce the successful completion of its cannabinoid sol-gel program (the “Sol-gel Program”) with the University of Queensland (“UQ”) and UniQuest Pty Ltd. (“UniQuest).
The final report confirms the successful chemical profiling of the solvent-derived cannabinoid extracts from cannabis plant species, which has provided the Company valuable information for formulation development using cannabinoid sol-gels. This enables PreveCeutical to control the quality of batch-to-batch variations in plant extract chemistries.  This will provide optimization of sol-gel formulation strategies.  PreveCeutical will now be able to develop and commercialize different combinations of the cannabinoid extracts to be infused into sol-gel formulations for appropriate treatments of different ailments.  PreveCeutical’s objectives are to develop, commercialize, and seek other third party clinical-proven formulations to be infused with the sol-gel delivery platform.
The cannabinoid Sol-gel Program for nose-to-brain delivery has been developed to be water-soluble without alcohol or solvent content.  The benefits associated with this is that it will be available for neo-natal, seniors, religious, and individual personal choices.  
Historical information of the Sol-gel Program is available as follows:
  1.  Extraction and chemical fingerprinting of cannabis extracts (news releases on September 4, 2018, and November 5, 2018).
  1. Infusion of cannabis extracts, acid and neutral CBD forms (news release November 20, 2018), into wholly water-based sol-gels, using FDA approved excipients (news release July 9, 2019).
  1. Effective delivery and sustained retention of the cannabis extract infused sol-gels from the nasal spray applicator to the nasal cavity (news release November 19, 2018).
  1. Confirmed safety of the cannabis extract infused sol-gels when applied to freshly explanted human mucosal tissue, with no elevation in clinically accepted biomarkers of acute toxicity (news release on January 8, 2020).
  1. Successful completion of its Sol-gel Program (news release on June 3, 2020).
Mr. Stephen Van Deventer, Chairman and CEO, commented, “We are excited with the research findings and successful in-vitro results from the cannabinoid Sol-gel Program. This will potentially create several therapeutic applications in managing controlled delivery of cannabinoidal combinations in clinical study settings, that would be of great value”.
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. 
PreveCeutical aims to be a leader in preventive health sciences.  The Company’s current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical™ peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook
On behalf of the Board of Directors of PreveCeutical                                                                     
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer at telephone:  +1 604 306 9669
Or Investor Relations ir@preveceutical.com                                                 
Forward-Looking Statements:
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the completion of the Sol-gel Program and the successful development of CBD sol-gel formulations, and the continued research interests of PreveCeutical, PreveCeutical’s anticipated business plans, and its prospects of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “will”, “pro forma”, “plans”, “expects”, “may”, “should”, “budget”, “schedules”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential”, “proposes” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations, including PreveCeutical’s research and development activities, performance, industry trends, growth opportunities, that PreveCeutical will be granted requisite expedited approvals by world health agencies for the results of the Sol-gel Program, and that PreveCeutical will be able to obtain the financing required to further carry out or commercialize the Sol-gel Program, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights needed to carry out future business activities.
Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to: complexities and delays in connection with research and development activities and the actual results of research and development activities including the successful development of CBD sol-gel formulations; the ability of PreveCeutical to, among other things, protect its respective intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities and obtaining expedited requisite approvals from world health agencies; and the ability of PreveCeutical to commercialize products, pursue business partnerships, complete their research programs as planned, including the Sol-gel Program, and obtain the financing required to carry out their planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate.  Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical’s filings are available at www.sedar.com. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Any link in this press release to external information or other resources is provided for reference only and such information or resources might change from time to time, and may include forward-looking statements as described above, and are subject to the above disclaimers under this heading forward-looking statements.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.
Sign up for the latest news and updates